1
|
Franchet C, Schwob R, Bataillon G, Syrykh C, Péricart S, Frenois FX, Penault-Llorca F, Lacroix-Triki M, Arnould L, Lemonnier J, Alliot JM, Filleron T, Brousset P. Bias reduction using combined stain normalization and augmentation for AI-based classification of histological images. Comput Biol Med 2024; 171:108130. [PMID: 38387381 DOI: 10.1016/j.compbiomed.2024.108130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 02/07/2024] [Accepted: 02/07/2024] [Indexed: 02/24/2024]
Abstract
Artificial intelligence (AI)-assisted diagnosis is an ongoing revolution in pathology. However, a frequent drawback of AI models is their propension to make decisions based rather on bias in training dataset than on concrete biological features, thus weakening pathologists' trust in these tools. Technically, it is well known that microscopic images are altered by tissue processing and staining procedures, being one of the main sources of bias in machine learning for digital pathology. So as to deal with it, many teams have written about color normalization and augmentation methods. However, only a few of them have monitored their effects on bias reduction and model generalizability. In our study, two methods for stain augmentation (AugmentHE) and fast normalization (HEnorm) have been created and their effect on bias reduction has been monitored. Actually, they have also been compared to previously described strategies. To that end, a multicenter dataset created for breast cancer histological grading has been used. Thanks to it, classification models have been trained in a single center before assessing its performance in other centers images. This setting led to extensively monitor bias reduction while providing accurate insight of both augmentation and normalization methods. AugmentHE provided an 81% increase in color dispersion compared to geometric augmentations only. In addition, every classification model that involved AugmentHE presented a significant increase in the area under receiving operator characteristic curve (AUC) over the widely used RGB shift. More precisely, AugmentHE-based models showed at least 0.14 AUC increase over RGB shift-based models. Regarding normalization, HEnorm appeared to be up to 78x faster than conventional methods. It also provided satisfying results in terms of bias reduction. Altogether, our pipeline composed of AugmentHE and HEnorm improved AUC on biased data by up to 21.7% compared to usual augmentations. Conventional normalization methods coupled with AugmentHE yielded similar results while being much slower. In conclusion, we have validated an open-source tool that can be used in any deep learning-based digital pathology project on H&E whole slide images (WSI) that efficiently reduces stain-induced bias and later on might help increase pathologists' confidence when using AI-based products.
Collapse
Affiliation(s)
- Camille Franchet
- Institut Universitaire du Cancer-Oncopole, Pathology Department, F-31059 Toulouse, France; Université Toulouse III-Paul Sabatier, F-31000 Toulouse, France.
| | - Robin Schwob
- Thales Services Numériques, Augmented data department, F-31670 Labège, France
| | - Guillaume Bataillon
- Institut Universitaire du Cancer-Oncopole, Pathology Department, F-31059 Toulouse, France
| | - Charlotte Syrykh
- Institut Universitaire du Cancer-Oncopole, Pathology Department, F-31059 Toulouse, France
| | - Sarah Péricart
- Institut Universitaire du Cancer-Oncopole, Pathology Department, F-31059 Toulouse, France
| | | | - Frédérique Penault-Llorca
- Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, France
| | - Magali Lacroix-Triki
- Département de Pathologie, Gustave-Roussy Cancer Campus, F-94805 Villejuif, France
| | - Laurent Arnould
- Department of Pathology and Tumor Biology, Centre Georges François Leclerc, Dijon, France
| | | | - Jean-Marc Alliot
- Institut de Recherche en Informatique de Toulouse, Toulouse University, Toulouse, France; CHU Toulouse, Toulouse, France
| | - Thomas Filleron
- Institut Universitaire du Cancer-Oncopole, Institut Claudius Regaud, Biostatistics & Health Data Science Unit, F-31059 Toulouse, France
| | - Pierre Brousset
- Institut Universitaire du Cancer-Oncopole, Pathology Department, F-31059 Toulouse, France; Université Toulouse III-Paul Sabatier, F-31000 Toulouse, France; Laboratoire d'Excellence Toulouse Cancer-TOUCAN, UMR1037 CRCT, F-31037 Toulouse, France.
| |
Collapse
|
2
|
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E. BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases. Haematologica 2024; 109:493-508. [PMID: 37560801 PMCID: PMC10828791 DOI: 10.3324/haematol.2023.283209] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 07/31/2023] [Indexed: 08/11/2023] Open
Abstract
The t(14;19)(q32;q13) often juxtaposes BCL3 with immunoglobulin heavy chain (IGH) resulting in overexpression of the gene. In contrast to other oncogenic translocations, BCL3 rearrangement (BCL3-R) has been associated with a broad spectrum of lymphoid neoplasms. Here we report an integrative whole-genome sequence, transcriptomic, and DNA methylation analysis of 13 lymphoid neoplasms with BCL3-R. The resolution of the breakpoints at single base-pair revealed that they occur in two clusters at 5' (n=9) and 3' (n=4) regions of BCL3 associated with two different biological and clinical entities. Both breakpoints were mediated by aberrant class switch recombination of the IGH locus. However, the 5' breakpoints (upstream) juxtaposed BCL3 next to an IGH enhancer leading to overexpression of the gene whereas the 3' breakpoints (downstream) positioned BCL3 outside the influence of the IGH and were not associated with its expression. Upstream BCL3-R tumors had unmutated IGHV, trisomy 12, and mutated genes frequently seen in chronic lymphocytic leukemia (CLL) but had an atypical CLL morphology, immunophenotype, DNA methylome, and expression profile that differ from conventional CLL. In contrast, downstream BCL3-R neoplasms were atypical splenic or nodal marginal zone lymphomas (MZL) with mutated IGHV, complex karyotypes and mutated genes typical of MZL. Two of the latter four tumors transformed to a large B-cell lymphoma. We designed a novel fluorescence in situ hybridization assay that recognizes the two different breakpoints and validated these findings in 17 independent tumors. Overall, upstream or downstream breakpoints of BCL3-R are mainly associated with two subtypes of lymphoid neoplasms with different (epi)genomic, expression, and clinicopathological features resembling atypical CLL and MZL, respectively.
Collapse
Affiliation(s)
- Anna Carbo-Meix
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona
| | - Francesca Guijarro
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Luojun Wang
- Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Marta Grau
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona
| | - Romina Royo
- Barcelona Supercomputing Center (BSC), Barcelona
| | - Gerard Frigola
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Heribert Playa-Albinyana
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
| | - Marco M Buhler
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich
| | - Guillem Clot
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona
| | - Marti Duran-Ferrer
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
| | - Junyan Lu
- European Molecular Biology Laboratory, Heidelberg
| | - Isabel Granada
- Department of Hematology-Laboratory, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona
| | - Maria-Joao Baptista
- Department of Hematology-Laboratory, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona
| | - Jose-Tomas Navarro
- Department of Hematology-Laboratory, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona
| | - Blanca Espinet
- Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain and Translational Research on Hematological Neoplasms Group (GRETNHE) - Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona
| | - Anna Puiggros
- Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain and Translational Research on Hematological Neoplasms Group (GRETNHE) - Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona
| | - Gustavo Tapia
- Department of Pathology, Hospital Germans Trias i Pujol, Badalona
| | - Laura Bandiera
- Anatomia Istologia Patologica e Citogenetica, Dipartimento Ematologia, Oncologia e Medicina Molecolare, Niguarda Cancer Center, Milano
| | - Gabriella De Canal
- Anatomia Istologia Patologica e Citogenetica, Dipartimento Ematologia, Oncologia e Medicina Molecolare, Niguarda Cancer Center, Milano
| | - Emanuela Bonoldi
- Anatomia Istologia Patologica e Citogenetica, Dipartimento Ematologia, Oncologia e Medicina Molecolare, Niguarda Cancer Center, Milano
| | - Fina Climent
- Department o f Pathology, H ospital Universitari d e Bellvitge, I nstitut d'Investigació B iomèdica d e Bellvitge (IDIBELL), L'Hospitalet De Llobregat
| | | | - Mariana Fernandez-Caballero
- Department of Hematology-Laboratory, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona
| | - Esmeralda De la Banda
- Laboratory of Hematology, Hospital Universitari Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet De Llobregat
| | | | | | - Dolors Vela
- Hematologia Clínica, Hospital General de Granollers, Granollers
| | - Maria Rozman
- Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Marta Aymerich
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Charlotte Syrykh
- Department of Pathology, Toulouse University Hospital Center, Cancer Institute University of Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse CEDEX 9
| | - Pierre Brousset
- Department of Pathology, Toulouse University Hospital Center, Cancer Institute University of Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse CEDEX 9, France; INSERM UMR1037 Cancer Research Center of Toulouse (CRCT), ERL 5294 National Center for Scientific Research (CNRS), University of Toulouse III Paul-Sabatier, Toulouse, France; Institut Carnot Lymphome CALYM, Laboratoire d'Excellence 'TOUCAN', Toulouse
| | - Miguel Perera
- Hematology Department, Hospital Dr Negrín, Las Palmas de Gran Canaria
| | - Lucrecia Yanez
- Hematology Department, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Valdecilla (IDIVAL), Santander
| | | | - Esperanza Tuset
- Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona
| | - Thorsten Zenz
- Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zurich
| | - James R Cook
- Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
| | - Steven H Swerdlow
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Jose I Martin-Subero
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
| | - Dolors Colomer
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universitat de Barcelona, Barcelona
| | - Estella Matutes
- Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona
| | - Silvia Bea
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universitat de Barcelona, Barcelona
| | - Dolors Costa
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
| | - Ferran Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
| | - Elias Campo
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, laboratory of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universitat de Barcelona, Barcelona.
| |
Collapse
|
3
|
Syrykh C, Pons-Brun B, Russiñol N, Playa-Albinyana H, Baumann T, Duran-Ferrer M, Kulis M, Carbó-Meix A, Mozas P, Alcoceba M, González M, Navarro-Bailón A, Colado E, Payer ÁR, Aymerich M, Terol MJ, Lu J, Knisbacher BA, Hahn CK, Ruiz-Gaspà S, Enjuanes A, Wu CJ, Getz G, Zenz T, López-Guillermo A, Martín-Subero JI, Colomer D, Delgado J, Campo E, Nadeu F. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Adv 2023; 7:7384-7391. [PMID: 37505099 PMCID: PMC10726246 DOI: 10.1182/bloodadvances.2023010132] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 07/12/2023] [Accepted: 07/12/2023] [Indexed: 07/29/2023] Open
Affiliation(s)
- Charlotte Syrykh
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - Berta Pons-Brun
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Núria Russiñol
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Heribert Playa-Albinyana
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| | | | - Martí Duran-Ferrer
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| | - Marta Kulis
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Anna Carbó-Meix
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Pablo Mozas
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
| | - Miguel Alcoceba
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Biología Molecular e Histocompatibilidad, Instituto de Investigación Biomédica de Salamanca-Hospital Universitario, Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, University of Salamanca-Spanish National Research Council, Salamanca, Spain
| | - Marcos González
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Biología Molecular e Histocompatibilidad, Instituto de Investigación Biomédica de Salamanca-Hospital Universitario, Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, University of Salamanca-Spanish National Research Council, Salamanca, Spain
| | - Almudena Navarro-Bailón
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Biología Molecular e Histocompatibilidad, Instituto de Investigación Biomédica de Salamanca-Hospital Universitario, Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, University of Salamanca-Spanish National Research Council, Salamanca, Spain
| | - Enrique Colado
- Servicio de Hematología y Hemoterapia, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Ángel R. Payer
- Servicio de Hematología y Hemoterapia, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Marta Aymerich
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
| | - María J. Terol
- Servicio de Hematología, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain
| | - Junyan Lu
- European Molecular Biology Laboratory, Heidelberg, Germany
| | - Binyamin A. Knisbacher
- The Broad Institute of MIT and Harvard, Cambridge, MA
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
| | - Cynthia K. Hahn
- The Broad Institute of MIT and Harvard, Cambridge, MA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - Sílvia Ruiz-Gaspà
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Anna Enjuanes
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Catherine J. Wu
- The Broad Institute of MIT and Harvard, Cambridge, MA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Boston, MA
- Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | - Gad Getz
- The Broad Institute of MIT and Harvard, Cambridge, MA
- Harvard Medical School, Boston, MA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA
- Department of Pathology, Massachusetts General Hospital, Boston, MA
| | - Thorsten Zenz
- Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zurich, Switzerland
| | - Armando López-Guillermo
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - José I. Martín-Subero
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Universitat de Barcelona, Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
| | - Dolors Colomer
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - Julio Delgado
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - Elías Campo
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
- Hospital Clínic of Barcelona, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - Ferran Nadeu
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| |
Collapse
|
4
|
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 2023; 8:101628. [PMID: 37713929 PMCID: PMC10594022 DOI: 10.1016/j.esmoop.2023.101628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/14/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs). MATERIALS AND METHODS To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories. The retrospective survey focussed on laboratory organisation and daily EGFR testing practice of pathologists and molecular biologists between 2018 and 2021. RESULTS TATs varied greatly both between and within countries. These discrepancies may be partly due to reflex testing practices, as 20.8% of laboratories carried out EGFR testing only at the request of the clinician. Many laboratories across Europe still favour single-test sequencing as a primary method of EGFR mutation identification; 32.7% indicated that they only used targeted techniques and 45.1% used single-gene testing followed by next-generation sequencing (NGS), depending on the case. Reported testing rates were consistent over time with no significant decrease in the number of EGFR tests carried out in 2020, despite the increased pressure faced by testing facilities during the COVID-19 pandemic. ISO 15189 accreditation was reported by 42.0% of molecular biology laboratories for single-test sequencing, and by 42.3% for NGS. 92.5% of laboratories indicated they regularly participate in an external quality assessment scheme. CONCLUSIONS These results highlight the strong heterogeneity of EGFR testing that still occurs within thoracic pathology and molecular biology laboratories across Europe. Even among expert testing facilities there is variability in testing capabilities, TAT, reflex testing practice and laboratory accreditation, stressing the need to harmonise reimbursement technologies and decision-making algorithms in Europe.
Collapse
Affiliation(s)
- P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France.
| | - F Calabrese
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - I Kern
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J Adam
- Department of Pathology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - A Alarcão
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - I Alborelli
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - N T Anton
- Department of Genetics, University Hospital Bichat-Claude Bernard, Paris University, Paris, France
| | - A Arndt
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - A Avdalyan
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - M Barberis
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - H Bégueret
- Department of Pathology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Pessac, France
| | - B Bisig
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - H Blons
- Pharmacogenomics and Molecular Oncology Unit, Biochemistry Department, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - P Boström
- Department of Pathology, Turku University Hospital, Turku, Finland
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - G Bubanovic
- Laboratory for Molecular Pathology, Department of Pathology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia
| | - A Buisson
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - A Caliò
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - M Cannone
- Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy
| | - L Carvalho
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - C Caumont
- Department of Tumor Biology, University Hospital of Bordeaux, Hospital Haut-Lévêque, Pessac, France
| | - A Cayre
- Department of Biopathology, Jean Perrin Centre, Clermont-Ferrand, France
| | - L Chalabreysse
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - M P Chenard
- Department of Pathology, University Hospital of Strasbourg, 67098 Strasbourg, France
| | - E Conde
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - M C Copin
- Department of Pathology, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - J F Côté
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - N D'Haene
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium
| | - H Y Dai
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - L de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - P Delongova
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - A Fabre
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - F Ferenc
- Department of Pathology, University of Oradea, Oradea, Romania
| | - F Forest
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F de Fraipont
- Medical Unit of Molecular Genetic (Hereditary Diseases and Oncology), Grenoble University Hospital, Grenoble, France
| | - M Garcia-Martos
- Department of Pathology, Gregorio Marañón General University Hospital, Madrid, Spain
| | - G Gauchotte
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France
| | - R Geraghty
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - E Guerin
- Department of Molecular Cancer Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France
| | - D Guerrero
- Biomedical Research Centre, Navarra Health Service, Pamplona, Navarra, Spain
| | - S Hernandez
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - P Hurník
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | - B Jean-Jacques
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - K Kashofer
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - D Kazdal
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - S Lantuejoul
- Department of Biopathology, Centre Leon Berard Unicancer and Pathology Research Platform, Cancer Research Center of Lyon (CRCL), Lyon, France
| | - C Leonce
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - A Lupo
- Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - U Malapelle
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - R Matej
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - J L Merlin
- Department of Biopathology, Institut de Cancérologie de Lorraine, University of Lorraine, Vandoeuvre-Les-Nancy, France
| | - K D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - A Morel
- Department of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France
| | - A Mutka
- HUSLAB, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - N Normanno
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - P Ovidiu
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Panizo
- Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M G Papotti
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - E Parobkova
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - G Pasello
- Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - P Pauwels
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - F Penault-Llorca
- Department of Pathology, Clermont Auvergne University, "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, Clermont-Ferrand, France
| | - T Picot
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - N Piton
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - A Pittaro
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - G Planchard
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - N Poté
- Department of Pathology, Hospital Bichat Bichat, Assistance Publique Hôpitaux de Paris; Université Paris Cité, Paris, France
| | - T Radonic
- Department of Pathology, Amsterdam University Medical Center, VUMC, University of Amsterdam, Amsterdam, Netherlands
| | - I Rapa
- Pathology Unit, San Luigi Hospital, Orbassano Turin, Italy
| | - A Rappa
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - C Roma
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - M Rot
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J C Sabourin
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - I Salmon
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium; CurePath, Jumet, Belgium
| | - S Savic Prince
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - A Scarpa
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - E Schuuring
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - I Serre
- Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, University of Montpellier, 80 Avenue Augustin Fliche, Montpellier, France
| | - V Siozopoulou
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - D Sizaret
- Department of Pathology, CHRU Tours - Hôpital Trousseau, Chambray-lès-Tours, France
| | - S Smojver-Ježek
- Division for Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Solassol
- Solid Tumour Laboratory, Pathology and Oncobiology Department, CHU Montpellier, University of Montpellier, Montpellier, France
| | - K Steinestel
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - J Stojšić
- Department of Thoracic Pathology, Section of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia
| | - C Syrykh
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - S Timofeev
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - G Troncone
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Uguen
- Department of Pathological Anatomy and Cytology, CHRU de Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, CHU de Brest, Brest, France
| | - S Valmary-Degano
- Department of Pathology, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France
| | - A Vigier
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - M Volante
- Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy
| | - S G F Wahl
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - M Ilié
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| |
Collapse
|
5
|
Fiévet L, Espagnolle N, Gerovska D, Bernard D, Syrykh C, Laurent C, Layrolle P, De Lima J, Justo A, Reina N, Casteilla L, Araúzo-Bravo MJ, Naji A, Pagès JC, Deschaseaux F. Single-cell RNA sequencing of human non-hematopoietic bone marrow cells reveals a unique set of inter-species conserved biomarkers for native mesenchymal stromal cells. Stem Cell Res Ther 2023; 14:229. [PMID: 37649081 PMCID: PMC10469496 DOI: 10.1186/s13287-023-03437-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 07/28/2023] [Indexed: 09/01/2023] Open
Abstract
BACKGROUND Native bone marrow (BM) mesenchymal stem/stromal cells (BM-MSCs) participate in generating and shaping the skeleton and BM throughout the lifespan. Moreover, BM-MSCs regulate hematopoiesis by contributing to the hematopoietic stem cell niche in providing critical cytokines, chemokines and extracellular matrix components. However, BM-MSCs contain a heterogeneous cell population that remains ill-defined. Although studies on the taxonomy of native BM-MSCs in mice have just started to emerge, the taxonomy of native human BM-MSCs remains unelucidated. METHODS By using single-cell RNA sequencing (scRNA-seq), we aimed to define a proper taxonomy for native human BM non-hematopoietic subsets including endothelial cells (ECs) and mural cells (MCs) but with a focal point on MSCs. To this end, transcriptomic scRNA-seq data were generated from 5 distinct BM donors and were analyzed together with other transcriptomic data and with computational biology analyses at different levels to identify, characterize and classify distinct native cell subsets with relevant biomarkers. RESULTS We could ascribe novel specific biomarkers to ECs, MCs and MSCs. Unlike ECs and MCs, MSCs exhibited an adipogenic transcriptomic pattern while co-expressing genes related to hematopoiesis support and multilineage commitment potential. Furthermore, by a comparative analysis of scRNA-seq of BM cells from humans and mice, we identified core genes conserved in both species. Notably, we identified MARCKS, CXCL12, PDGFRA, and LEPR together with adipogenic factors as archetypal biomarkers of native MSCs within BM. In addition, our data suggest some complex gene nodes regulating critical biological functions of native BM-MSCs together with a preferential commitment toward an adipocyte lineage. CONCLUSIONS Overall, our taxonomy for native BM non-hematopoietic compartment provides an explicit depiction of gene expression in human ECs, MCs and MSCs at single-cell resolution. This analysis helps enhance our understanding of the phenotype and the complexity of biological functions of native human BM-MSCs.
Collapse
Affiliation(s)
- Loïc Fiévet
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
- CHU de Toulouse, IFB, Hôpital Purpan, Toulouse, France
| | - Nicolas Espagnolle
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Daniela Gerovska
- Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014, San Sebastián, Spain
- Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940, Leioa, Spain
| | - David Bernard
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Charlotte Syrykh
- Department d'Anatomie Pathologique, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - Camille Laurent
- Department d'Anatomie Pathologique, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - Pierre Layrolle
- Tonic Inserm/UPS UMR 1214, CHU Purpan Hospital, Toulouse, France
- UMR 1238 Inserm, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, Nantes, France
| | - Julien De Lima
- UMR 1238 Inserm, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, Nantes, France
| | - Arthur Justo
- Department de Chirurgie Orthopédique, Pierre Paul Riquet, Hôpital Purpan, Toulouse, France
| | - Nicolas Reina
- Department de Chirurgie Orthopédique, Pierre Paul Riquet, Hôpital Purpan, Toulouse, France
| | - Louis Casteilla
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Marcos J Araúzo-Bravo
- Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014, San Sebastián, Spain
- Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940, Leioa, Spain
| | - Abderrahim Naji
- Department of Environmental Medicine, Cooperative Medicine Unit, Research and Education Faculty, Medicine Science Cluster, Nankoku, Kochi Prefecture, Japan
| | - Jean-Christophe Pagès
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
- CHU de Toulouse, IFB, Hôpital Purpan, Toulouse, France
| | - Frédéric Deschaseaux
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France.
| |
Collapse
|
6
|
Syrykh C, Laurent C. [Histoseminar: "The contribution of new molecular biology techniques in the diagnosis of lymphoma: Myth or reality?". Cases No. 5 & 6]. Ann Pathol 2023; 43:139-145. [PMID: 36822905 DOI: 10.1016/j.annpat.2023.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Accepted: 01/05/2023] [Indexed: 02/23/2023]
Affiliation(s)
- Charlotte Syrykh
- Laboratoire de pathologie, institut universitaire du cancer-Toulouse, oncopole, 1, avenue Iréne-Joliot-Curie, 31059 Toulouse cedex 9, France.
| | - Camille Laurent
- Laboratoire de pathologie, institut universitaire du cancer-Toulouse, oncopole, 1, avenue Iréne-Joliot-Curie, 31059 Toulouse cedex 9, France
| |
Collapse
|
7
|
Laurent C, Traverse-Glehen A, Xerri L, Syrykh C. Histoséminaire de la Société française de pathologie « apport des nouvelles techniques de biologie moléculaire dans le diagnostic des lymphomes : mythe ou réalité ? » - Pré-Test. Ann Pathol 2023. [DOI: 10.1016/j.annpat.2023.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
8
|
Phelippeau M, Lefebvre C, Jacob MC, Syrykh C, Ghelfi J, Carras S, Laurent C, Molina L, Valmary-Degano S. [Dasatinib-induced follicular lymphoid hyperplasia, an entity to know]. Ann Pathol 2023; 43:45-51. [PMID: 36266200 DOI: 10.1016/j.annpat.2022.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 07/30/2022] [Accepted: 09/14/2022] [Indexed: 11/05/2022]
Abstract
Follicular lymphoid hyperplasia induced by dasatinib is an entity recently described. It is sometimes difficult to rule out the diagnostic of small B-cell lymphoma. Usually, the node is swollen, with follicular architecture conserved, composed by germinal centers with variable size and shape, with a hight number of mitoses and tingible bodies macrophages inside. Follicular lymphoid hyperplasia is isolated or associated with multiple reactive patterns. The immunohistochemical profil of germinal centers is CD20+, CD10+, BCL6+, BCL2-. Swollen node disappears in a short time after dasatinib discontinuation. Clinicians and pathologists need to be aware of this entity, so as not to avoid mistakenly suspect lymphoma when lymphadenopathy occurs in a patient with chronic myeloid leukemia treated with dasatinib.
Collapse
Affiliation(s)
- Mona Phelippeau
- Service d'anatomie et cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - Christine Lefebvre
- Laboratoire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | | | - Charlotte Syrykh
- Service d'anatomie et cytologie pathologiques, Institut Universitaire du Cancer de Toulouse Toulouse - Oncopole, 31000 Toulouse, France
| | - Julien Ghelfi
- Departement de radiologie, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - Sylvain Carras
- Laboratoire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France; Université de Grenoble-Alpes, Inserm U1209, CNRS UMR5309, Institut pour l'avancée des biosciences (IAB), 38000 Grenoble, France; Service d'hématologie, Centre Hospitalo-Universitaire de Grenoble-Alpes, 38000 Grenoble, France
| | - Camille Laurent
- Service d'anatomie et cytologie pathologiques, Institut Universitaire du Cancer de Toulouse Toulouse - Oncopole, 31000 Toulouse, France
| | - Lysiane Molina
- Service d'hématologie, Centre Hospitalo-Universitaire de Grenoble-Alpes, 38000 Grenoble, France
| | - Séverine Valmary-Degano
- Service d'anatomie et cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France; Université de Grenoble-Alpes, Inserm U1209, CNRS UMR5309, Institut pour l'avancée des biosciences (IAB), 38000 Grenoble, France.
| |
Collapse
|
9
|
Hofman V, Heeke S, Bontoux C, Chalabreysse L, Barritault M, Bringuier PP, Fenouil T, Benzerdjeb N, Begueret H, Merlio JP, Caumont C, Piton N, Sabourin JC, Evrard S, Syrykh C, Vigier A, Brousset P, Mazieres J, Long-Mira E, Benzaquen J, Boutros J, Allegra M, Tanga V, Lespinet-Fabre V, Salah M, Bonnetaud C, Bordone O, Lassalle S, Marquette CH, Ilié M, Hofman P. Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC. JTO Clin Res Rep 2022; 4:100457. [PMID: 36718140 PMCID: PMC9883235 DOI: 10.1016/j.jtocrr.2022.100457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 12/23/2022] [Accepted: 12/27/2022] [Indexed: 12/31/2022] Open
Abstract
Introduction Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is critical for optimal clinical decision-making. Here, we compared two ultrafast gene fusion assays (UFGFAs) using NGS (Genexus, Oncomine Precision Assay, Thermo Fisher Scientific) and a multiplex reverse-transcriptase polymerase chain reaction (Idylla, GeneFusion Assay, Biocartis) approach at diagnosis in a retrospective series of 195 NS-NSCLC cases and five extrapulmonary tumors with a known NTRK fusion. Methods A total of 195 NS-NSCLC cases (113 known gene fusions and 82 wild-type tumors) were included retrospectively. To validate the detection of a NTRK fusion, we added five NTRK-positive extrathoracic tumors. The diagnostic performance of the two UFGFAs and standard procedures was compared. Results The accuracy was 92.3% and 93.1% for Idylla and Genexus, respectively. Both systems improved the sensitivity for detection by including a 5'-3' imbalance analysis. Although detection of ROS1, MET exon 14 skipping, and RET was excellent with both systems, ALK fusion detection was reduced with sensitivities of 87% and 88%, respectively. Idylla had a limited sensitivity of 67% for NTRK fusions, in which only an imbalance assessment was used. Conclusions UFGFA using NGS and reverse-transcriptase polymerase chain reaction approaches had an equal level of detection of gene fusion but with some technique-specific limitations. Nevertheless, UFGFA detection in routine clinical care is feasible with both systems allowing faster initiation of therapy and a broad degree of screening.
Collapse
Affiliation(s)
- Véronique Hofman
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France
| | - Simon Heeke
- Department of Thoracic/Head & Neck Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, Texas
| | - Christophe Bontoux
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France
| | - Lara Chalabreysse
- Department of Pathology, Hospices Civils de Lyon, Groupement Hospitalier Est - HCL, Bron, France, University Claude Bernard, Lyon, France
| | - Marc Barritault
- Department of Pathology, Molecular Biology of Tumors, Hospices Civils de Lyon, Groupement Hospitalier Est - HCL, Bron, France
| | - Pierre Paul Bringuier
- Department of Pathology, Molecular Biology of Tumors, Hospices Civils de Lyon, Groupement Hospitalier Est - HCL, Bron, France
| | - Tanguy Fenouil
- Department of Pathology, Hospices Civils de Lyon, Groupement Hospitalier Est - HCL, Bron, France, University Claude Bernard, Lyon, France
| | - Nazim Benzerdjeb
- Department of Pathology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France, University Claude Bernard, Lyon, France,Department of Cancer Cell Plasticity, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France
| | - Hugues Begueret
- Department of Pathology, Centre Hospitalier Universitaire Bordeaux, Hôpital Haut-Lévêque, Pessac, France
| | - Jean Philippe Merlio
- Department of Histology and Molecular Pathology of Tumors, Centre Hospitalier Universitaire Bordeaux, Pessac, France
| | - Charline Caumont
- Department of Histology and Molecular Pathology of Tumors, Centre Hospitalier Universitaire Bordeaux, Pessac, France
| | - Nicolas Piton
- Department of Pathology and INSERM U1245, CHU de Rouen, Normandie Université, Rouen, France
| | | | - Solène Evrard
- Department of Pathology, IUCT-Oncopole, Toulouse, France
| | | | - Anna Vigier
- Department of Pathology, IUCT-Oncopole, Toulouse, France
| | | | - Julien Mazieres
- Department of Pneumology, CHU Toulouse-Hôpital Larrey, Université Paul Sabatier, Toulouse, France
| | - Elodie Long-Mira
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France
| | - Jonathan Benzaquen
- FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France,Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France
| | - Jacques Boutros
- FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France,Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France
| | - Maryline Allegra
- Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France
| | - Virginie Tanga
- Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France
| | - Virginie Lespinet-Fabre
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France
| | - Myriam Salah
- Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France
| | | | - Olivier Bordone
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France
| | - Sandra Lassalle
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France
| | - Charles-Hugo Marquette
- FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France,Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France
| | - Marius Ilié
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France
| | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France,Hospital-Integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France,FHU OncoAge, Hôpital Pasteur, Université Côte d’Azur, Nice, France,Inserm U1081, CNRS UMR 7413, IRCAN, Nice, France,Corresponding author. Address for correspondence: Paul Hofman, MD, PhD, Laboratoire de Pathologie Clinique et Expérimentale, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, 30 Voie Romaine, 06000 Nice, France.
| |
Collapse
|
10
|
Lamaison C, Ferrant J, Gravelle P, Traverse-Glehen A, Ghesquières H, Tosolini M, Rossi C, Ysebaert L, Brousset P, Laurent C, Syrykh C. Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma. Cancers (Basel) 2022; 14:cancers14194893. [PMID: 36230815 PMCID: PMC9563296 DOI: 10.3390/cancers14194893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 09/16/2022] [Accepted: 09/29/2022] [Indexed: 11/16/2022] Open
Abstract
Despite the success of standard front-line chemotherapy, 20% of classical Hodgkin lymphoma (cHL) patients still relapse or have refractory disease (r/r), and a subset of them die due to disease progression. There is a critical lack of predictive factors for early identification of those r/r patients who may benefit from new therapeutic strategies. This study aimed to evaluate the dynamic expression of 586 immune-related genes in a cohort of 42 cHL patients including 30 r/r cHL after first-line chemotherapy. Gene expression profiling (GEP) using NanoString technology identified a 19-gene immune signature at diagnosis predictive of cHL relapse, but dependent on histological subtypes. Genes related to tumor survival were found upregulated while genes related to B-lineage were downregulated at diagnosis in r/r nodular sclerosis cHL. In contrast to the mixed-cellularity subtype, comparative GEP analyses between paired diagnosis/relapse biopsies of nodular sclerosis cHL showed 118 differentially expressed genes, supporting an immune contexture switch at relapse with upregulation of immunosuppressive cytokines, such as LGALS1 and TGFB1, and downregulation of the T-cell co-stimulatory receptor ICOS. These results indicate that the predictive value of immune signature in cHL is strongly influenced by histological subtype which should be considered when assessing new immunotherapy target strategies.
Collapse
Affiliation(s)
- Claire Lamaison
- Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France
| | - Juliette Ferrant
- Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France
- Institut National de la Santé et de la Recherche Médicale, INSERM, Unité Mixte de Recherche U1236, Université Rennes 1, Établissement Français du Sang Bretagne, 35000 Rennes, France
| | - Pauline Gravelle
- Service d’Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Laboratoire d’Excellence TOUCAN, 31037 Toulouse, France
| | | | - Hervé Ghesquières
- Service d’Hématologie, Centre Hospitalier Universitaire de Lyon-Sud, Université Claude Bernard Lyon-1, Pierre-Bénite, 69495 Lyon, France
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Laboratoire d’Excellence TOUCAN, 31037 Toulouse, France
| | - Cédric Rossi
- Service d’Hématologie, Centre Hospitalier Universitaire Dijon, Hôpital François Mitterrand, 21000 Dijon, France
| | - Loic Ysebaert
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Laboratoire d’Excellence TOUCAN, 31037 Toulouse, France
- Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France
- Université de Toulouse III Paul Sabatier, 31062 Toulouse, France
| | - Pierre Brousset
- Service d’Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Laboratoire d’Excellence TOUCAN, 31037 Toulouse, France
- Université de Toulouse III Paul Sabatier, 31062 Toulouse, France
| | - Camille Laurent
- Service d’Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Laboratoire d’Excellence TOUCAN, 31037 Toulouse, France
- Université de Toulouse III Paul Sabatier, 31062 Toulouse, France
| | - Charlotte Syrykh
- Service d’Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France
- Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France
- Université de Toulouse III Paul Sabatier, 31062 Toulouse, France
- Correspondence: ; Tel.: +33-531156200
| |
Collapse
|
11
|
Hofman V, Heeke S, Bontoux C, Chalabreysse L, Barritault M, Bringuier P, Fenouil T, Benzerdjeb N, Begueret H, Merlio J, Caumont C, Piton N, Sabourin JC, Evrard S, Syrykh C, Vigier A, Brousset P, Mazières J, Long-Mira E, Benzaquen J, Tanga V, Lespinet-Fabre V, Lassalle S, Marquette CH, Ilié M, Hofman P. EP11.01-005 Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
12
|
Syrykh C, Schiratti JB, Brion E, Joubert C, Baia M, Marlot L, Maussion C, Danneaux LW, Bologna S, Briere J, Dartigues P, Gaulard P, Haioun C, Jardin F, Molina T, Tilly H, Gomez E, Sondaz D, Copie-Bergman C, Laurent C. 623MO Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
13
|
Leveque E, Rouch A, Syrykh C, Mazières J, Brouchet L, Valitutti S, Espinosa E, Lafouresse F. Phenotypic and Histological Distribution Analysis Identify Mast Cell Heterogeneity in Non-Small Cell Lung Cancer. Cancers (Basel) 2022; 14:cancers14061394. [PMID: 35326546 PMCID: PMC8946292 DOI: 10.3390/cancers14061394] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/04/2022] [Accepted: 03/07/2022] [Indexed: 02/04/2023] Open
Abstract
Simple Summary During the fight against tumor, some cells of the immune system such as cytotoxic lymphocytes eliminate tumoral cells while others such as tumor-associated macrophages favor tumor development. Mast cells (MCs) are multifaceted immune cells whose role in cancer is still poorly understood. Moreover, MCs are poorly characterized in the context of cancer and their presence in the tumor microenvironment has been reported to be either associated with good or bad prognosis. In this pilot study we characterized tumor-associated MCs (TAMCs) in lung cancer. We showed that TAMCs exhibited a typical phenotype and can be classified in two subsets according to alphaE integrin (CD103) expression. CD103+ TAMCs appeared more mature, more prone to interact with CD4+ T cells, and located closer to cancer cells than their CD103− counterpart. This study revealed that a high frequency of total TAMC correlated with better overall survival and progression free survival in patients and underlined MC heterogeneity in cancer. Abstract Mast cells (MCs) are multifaceted innate immune cells often present in the tumor microenvironment (TME). However, MCs have been only barely characterized in studies focusing on global immune infiltrate phenotyping. Consequently, their role in cancer is still poorly understood. Furthermore, their prognosis value is confusing since MCs have been associated with good and bad (or both) prognosis depending on the cancer type. In this pilot study performed on a surgical cohort of 48 patients with Non-Small Cell Lung Cancer (NSCLC), we characterized MC population within the TME and in matching non-lesional lung areas, by multicolor flow cytometry and confocal microscopy. Our results showed that tumor-associated MCs (TAMCs) harbor a distinct phenotype as compared with MCs present in non-lesional counterpart of the lung. Moreover, we found two TAMCs subsets based on the expression of CD103 (also named alphaE integrin). CD103+ TAMCs appeared more mature, more prone to interact with CD4+ T cells, and located closer to cancer cells than their CD103− counterpart. In spite of these characteristics, we did not observe a prognosis advantage of a high frequency of CD103+ TAMCs, while a high frequency of total TAMC correlated with better overall survival and progression free survival. Together, this study reveals that TAMCs constitute a heterogeneous population and indicates that MC subsets should be considered for patients’ stratification and management in future research.
Collapse
Affiliation(s)
- Edouard Leveque
- Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037, INSERM, UMR5071, CNRS, Université Toulouse 3, 31037 Toulouse, France; (E.L.); (A.R.); (S.V.); (E.E.)
| | - Axel Rouch
- Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037, INSERM, UMR5071, CNRS, Université Toulouse 3, 31037 Toulouse, France; (E.L.); (A.R.); (S.V.); (E.E.)
- Thoracic Surgery Department, Hôpital Larrey, CHU Toulouse, 31000 Toulouse, France;
| | - Charlotte Syrykh
- Department of Pathology, Institut Universitaire du Cancer—Oncopole de Toulouse, 31059 Toulouse, France;
| | - Julien Mazières
- Thoracic Oncology Department, Hôpital Larrey, CHU Toulouse, 31000 Toulouse, France;
| | - Laurent Brouchet
- Thoracic Surgery Department, Hôpital Larrey, CHU Toulouse, 31000 Toulouse, France;
| | - Salvatore Valitutti
- Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037, INSERM, UMR5071, CNRS, Université Toulouse 3, 31037 Toulouse, France; (E.L.); (A.R.); (S.V.); (E.E.)
- Department of Pathology, Institut Universitaire du Cancer—Oncopole de Toulouse, 31059 Toulouse, France;
| | - Eric Espinosa
- Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037, INSERM, UMR5071, CNRS, Université Toulouse 3, 31037 Toulouse, France; (E.L.); (A.R.); (S.V.); (E.E.)
| | - Fanny Lafouresse
- Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037, INSERM, UMR5071, CNRS, Université Toulouse 3, 31037 Toulouse, France; (E.L.); (A.R.); (S.V.); (E.E.)
- Correspondence:
| |
Collapse
|
14
|
Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M. "Accelerated phase" chronic lymphocytic leukemia: still an intermediate risk disease in the era of targeted therapies. Hematol Oncol 2022; 40:805-808. [PMID: 35246868 DOI: 10.1002/hon.2985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
N/A This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Léopoldine Lapierre
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Charlotte Syrykh
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Anatomopathologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Laetitia Largeaud
- Université de Toulouse, UPS, Toulouse, France.,Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Bastien Cabarrou
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de biostatistiques, Toulouse, France
| | - Thomas Filleron
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de biostatistiques, Toulouse, France
| | - Lucie Oberic
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Salim Kanoun
- Institut Claudius Regaud (ICR) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de médecine nucléaire, Toulouse, France
| | - Lucie Coster
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Camille Laurent
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Anatomopathologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Benoît Branco
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Noémie Gadaud
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Christian Récher
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Delphine Brechemier
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Oncogériatrie, Toulouse, France
| | - Laurent Balardy
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Oncogériatrie, Toulouse, France
| | - François Vergez
- Université de Toulouse, UPS, Toulouse, France.,Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Loïc Ysebaert
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | | |
Collapse
|
15
|
Larrauffie A, Syrykh C, Tavitian S, Comont T, Dion J. Activated PI3 Kinase Delta Syndrome Revealed by Vasculitis and Disseminated Toxoplasmosis. J Clin Immunol 2022; 42:688-690. [PMID: 35022947 DOI: 10.1007/s10875-021-01186-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 11/23/2021] [Indexed: 11/25/2022]
Affiliation(s)
- Aurore Larrauffie
- Department of Internal Medicine and Clinical Immunopathology - IUCT-Oncopole, Centre Hospitalier Universitaire de Toulouse, 1, avenue Irène-Joliot-Curie, 31059, Toulouse, France
| | - Charlotte Syrykh
- Department of Pathology - IUCT-Oncopole, Centre Hospitalier Universitaire de Toulouse, 1, avenue Irène-Joliot-Curie, 31059, Toulouse, France
| | - Suzanne Tavitian
- Department of Hematology - IUCT-Oncopole, Centre Hospitalier Universitaire de Toulouse, 1, avenue Irène-Joliot-Curie, 31059, Toulouse, France
| | - Thibault Comont
- Department of Internal Medicine and Clinical Immunopathology - IUCT-Oncopole, Centre Hospitalier Universitaire de Toulouse, 1, avenue Irène-Joliot-Curie, 31059, Toulouse, France
| | - Jeremie Dion
- Department of Internal Medicine and Clinical Immunopathology - IUCT-Oncopole, Centre Hospitalier Universitaire de Toulouse, 1, avenue Irène-Joliot-Curie, 31059, Toulouse, France.
| |
Collapse
|
16
|
Dupin N, Jary A, Boussouar S, Syrykh C, Gandjbakhche A, Bergeret S, Palich R. Current and Future Tools for Diagnosis of Kaposi's Sarcoma. Cancers (Basel) 2021; 13:cancers13235927. [PMID: 34885035 PMCID: PMC8657166 DOI: 10.3390/cancers13235927] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 11/16/2021] [Accepted: 11/23/2021] [Indexed: 12/04/2022] Open
Abstract
Simple Summary Kaposi’s sarcoma, a rare opportunistic tumor, is observed in four epidemiological conditions (AIDS-related, iatrogenic, endemic or classic KS). Although in most cases KS is an indolent disease, it can be locally aggressive and/or it can invade other organs than the skin, resulting in more severe presentations, especially in patients with severe immunosuppression. There is no consensus on the imaging workup that is necessary for either the initial staging of the disease or the follow-up. Future perspectives include the use of certain non-invasive imaging tools that may help to evaluate the clinical response to treatment, as well as certain new histological markers that may help in guiding the treatment planning for this atypical neoplasm. Abstract Kaposi’s sarcoma (KS) is a rare, atypical malignancy associated with immunosuppression and can be qualified as an opportunistic tumor, which responds to immune modulation or restoration. Four different epidemiological forms have been individualized (AIDS-related, iatrogenic, endemic or classic KS). Although clinical examination is sufficient to diagnose cutaneous lesions of KS, additional explorations are necessary in order to detect lesions involving other organs. New histological markers have been developed in recent years concerning the detection of HHV-8 latent or lytic proteins in the lesions, helping to confirm the diagnosis when it is clinically doubtful. More recently, the evaluation of the local immune response has also been shown to provide some guidance in choosing the appropriate therapeutic option when necessary. We also review the indication and the results of conventional radiological imaging and of non-invasive imaging tools such as 18F-fluoro-deoxy-glucose positron emission tomography, thermography and laser Doppler imaging for the diagnosis of KS and for the follow-up of therapeutic response in patients requiring systemic treatment.
Collapse
Affiliation(s)
- Nicolas Dupin
- Dermatology Department, Cochin Hospital, AP-HP, Institut Cochin, INSERM 1016, Université de Paris, 75014 Paris, France;
| | - Aude Jary
- Virology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, 75013 Paris, France;
| | - Samia Boussouar
- Cardiothoracic Imaging Unit, Pitié-Salpêtrière Hospital, AP-HP, ICAN Institute of Cardiometabolism and Nutrition, INSERM, Sorbonne University, 75013 Paris, France;
| | - Charlotte Syrykh
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, 31000 Toulouse, France;
| | - Amir Gandjbakhche
- Section on Analytical and Functional Biophotonics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA;
| | - Sébastien Bergeret
- Nuclear Medicine Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France;
| | - Romain Palich
- Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, 75013 Paris, France
- Correspondence: ; Tel.: +33-1-42-16-01-71; Fax: +33-1-42-16-04-45
| |
Collapse
|
17
|
Mouchel P, Syrykh C, Laurent C, Tavitian S, Gauthier M. First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy. Am J Hematol 2021; 96:755-756. [PMID: 33075158 DOI: 10.1002/ajh.26026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 10/13/2020] [Accepted: 10/15/2020] [Indexed: 12/16/2022]
Affiliation(s)
- Pierre‐Luc Mouchel
- Department of Hematology centre hospitalier universitaire de Toulouse Toulouse France
- Université Paul Sabatier Toulouse III Toulouse France
| | - Charlotte Syrykh
- Department of pathology Cancer University Institute of Toulouse Toulouse France
| | - Camille Laurent
- Université Paul Sabatier Toulouse III Toulouse France
- Department of pathology Cancer University Institute of Toulouse Toulouse France
| | - Suzanne Tavitian
- Department of Hematology centre hospitalier universitaire de Toulouse Toulouse France
| | - Martin Gauthier
- Department of Hematology centre hospitalier universitaire de Toulouse Toulouse France
- Université Paul Sabatier Toulouse III Toulouse France
| |
Collapse
|
18
|
Laurent C, Syrykh C, Herbaux C, Gat E, Gravelle P, Tarte K, Cartron G, Xerri L. A WIDE T‐CELL EXHAUSTION PATTERN IS FREQUENTIN THE TUMOR MICROENVIRONMENT OF RELAPSED/REFRACTORY B‐CELL LYMPHOMA PATIENTS AND COULD BE CIRCUMVENTED BY PDL1 BLOCKADE. Hematol Oncol 2021. [DOI: 10.1002/hon.10_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- C Laurent
- IUCT‐Oncopole Toulouse CRCT INSERM U1037 Pathology Toulouse France
| | - C Syrykh
- IUCT‐Oncopole Toulouse CRCT INSERM U1037 Pathology Toulouse France
| | - C Herbaux
- CHU Montepellier UMR CNRS 5235 Hematology Montpellier France
| | - E Gat
- LYSARC CHU Lyon Sud, LYSARC Pierre‐Bénite France
| | - P Gravelle
- IUCT‐Oncopole Toulouse CRCT INSERM U1037 Pathology Toulouse France
| | - K Tarte
- CHU Rennes Pontchaillou UMR U1236 Immunology Cell Therapy and Hematopoiesis Rennes France
| | - G Cartron
- CHU Montepellier UMR CNRS 5235 Hematology Montpellier France
| | - L Xerri
- Institut Paoli‐Calmettes Centre de Recherche en Cancérologie de Marseille INSERM U1068 CNRS UMR7258 Pathology Marseille France
| |
Collapse
|
19
|
Laurent C, Hamon M, Syrykh C, Adélaï J, Guille A, Parrens M, Dartigues P, Bardet A, Mescam L, Schiano De Colella J, Sujobert P, Besson C, Birnbaum D, Xerri L. RESISTANCE OF B‐CELL LYMPHOMAS TO CAR‐T CELL THERAPY IS ASSOCIATED WITH HISTOPHENOTYPICAL AND GENOMIC TUMOR CHANGES WHICH CAN INDUCE PROFOUND TRANS‐DIFFERENTIATION. Hematol Oncol 2021. [DOI: 10.1002/hon.190_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | - M. Hamon
- Hopital André Mignot Pathology Versailles France
| | | | - J. Adélaï
- IPC, Predictive Oncology/ CRCM Inserm CNRS AMU Marseille France
| | - A. Guille
- CRCM Predictive oncology Marseille France
| | - M. Parrens
- Hopital haut‐Lévéque, Pathology Bordeaux France
| | | | - A. Bardet
- Institut Paoli‐Calmettes pathology Marseille France
| | - L. Mescam
- Institut Paoli‐Calmettes pathology Marseille France
| | | | - P. Sujobert
- CHU Lyon‐Sud, Hématology Pierre‐Bénite France
| | - C. Besson
- Hopital André Mignot Pathology Versailles France
| | | | - L. Xerri
- Institut Paoli‐Calmettes pathology Marseille France
| |
Collapse
|
20
|
Gauthier M, Mouchel PL, Syrykh C, Couture G. Chronic myeloid leukemia revealed through focal bone lesions responding to imatinib: The bee's knees. Joint Bone Spine 2020; 88:105118. [PMID: 33346104 DOI: 10.1016/j.jbspin.2020.105118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 12/02/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Martin Gauthier
- Department of Hematology, centre hospitalier universitaire de Toulouse, IUCT-O, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France; Université Paul Sabatier Toulouse III, Toulouse, France.
| | - Pierre-Luc Mouchel
- Department of Hematology, centre hospitalier universitaire de Toulouse, IUCT-O, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France; Université Paul Sabatier Toulouse III, Toulouse, France
| | - Charlotte Syrykh
- Department of pathology, cancer university institute of Toulouse, Oncopole, Toulouse, France
| | - Guillaume Couture
- Department of rheumatology, University hospital of Toulouse, Toulouse, France
| |
Collapse
|
21
|
Rossi C, Tosolini M, Gravelle P, Pericart S, Kanoun S, Evrard S, Gilhodes J, Franchini DM, Amara N, Syrykh C, Bories P, Oberic L, Ysebaert L, Martin L, Ramla S, Robert P, Tabouret-Viaud C, Casasnovas RO, Fournié JJ, Bezombes C, Laurent C. Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 2020; 107:221-230. [PMID: 33327711 PMCID: PMC8719066 DOI: 10.3324/haematol.2020.263194] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Indexed: 11/09/2022] Open
Abstract
Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate PET metrics could be helpful to identify patients with a high risk of treatment failure with Rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline SUVmax was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, together with the tumor mutation profile. We report that baseline SUVmax >14.5 was associated with poorer PFS than baseline SUVmax ≤14.5 (HR=0.28; p=0.00046). Neither immune T-cell infiltration nor immune checkpoint expression were associated with baseline PET metrics. By contrast, FL samples with Ki-67 staining ≥10% showed enrichment of cell cycle/DNA genes (p=0.013) and significantly higher SUVmax values (p=0.007). Despite similar oncogenic pathway alterations in both SUVmax groups of FL samples, 4 out of 5 cases harboring the infrequent FOXO1 transcription factor mutation were seen in FL patients with SUVmax >14.5. Thus, high baseline SUVmax reflects FL tumor proliferation and, together with Ki-67 proliferative index, can be used to identify patients at risk of early relapse with R-chemotherapy.
Collapse
Affiliation(s)
- Cédric Rossi
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite, France; CHU Dijon, Hématologie clinique, Hôpital François Mitterrand, Dijon.
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse
| | - Pauline Gravelle
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite, France; Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Sarah Pericart
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Salim Kanoun
- Médecine Nucléaire, Institut universitaire du cancer Toulouse-Oncopole, Toulouse
| | - Solene Evrard
- Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Julia Gilhodes
- Bureau des essais cliniques, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse
| | - Don-Marc Franchini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite
| | - Nadia Amara
- Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Charlotte Syrykh
- Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Réseau Régional de Cancérologie, Onco-Occitanie, Institut Universitaire du Cancer Toulouse-Oncopole; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Pierre Bories
- Réseau Régional de Cancérologie, Onco-Occitanie, Institut Universitaire du Cancer Toulouse-Oncopole; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Lucie Oberic
- Service d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Loïc Ysebaert
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite, France.; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse
| | - Laurent Martin
- Département de pathologie, CHU Hôpital François Mitterrand, Dijon, France; INSERM UMR 1231 UFR Bourgogne
| | - Selim Ramla
- Département de pathologie, CHU Hôpital François Mitterrand, Dijon, France; INSERM UMR 1231 UFR Bourgogne
| | - Philippine Robert
- CHU Dijon, Hématologie clinique, Hôpital François Mitterrand, Dijon, France; INSERM UMR 1231 UFR Bourgogne
| | | | - René-Olivier Casasnovas
- CHU Dijon, Hématologie clinique, Hôpital François Mitterrand, Dijon, France; INSERM UMR 1231 UFR Bourgogne
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite
| | - Christine Bezombes
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite.
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; CALYM Carnot Institute, Pierre-Bénite, France; Département de pathologie, Institut Universitaire du Cancer de Toulouse, Toulouse.
| |
Collapse
|
22
|
Villeneuve T, Michaud M, Syrykh C, Catros F, Didier A. A silent retrocardiac mass revealing an IgG4-related disease. Respir Med Res 2020; 79:100800. [PMID: 33254091 DOI: 10.1016/j.resmer.2020.100800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 11/03/2020] [Accepted: 11/08/2020] [Indexed: 10/23/2022]
Affiliation(s)
- T Villeneuve
- Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, Toulouse, France.
| | - M Michaud
- Service de médecine interne, hôpital Joseph-Ducuing, Toulouse, France
| | - C Syrykh
- Service d'anatomie et cytologie pathologiques, institut universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - F Catros
- Service de médecine interne, hôpital Joseph-Ducuing, Toulouse, France
| | - A Didier
- Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, Toulouse, France
| |
Collapse
|
23
|
Del M, Angeles MA, Syrykh C, Martínez-Gómez C, Martínez A, Ferron G, Gabiache E, Oberic L. Primary B-Cell lymphoma of the uterine cervix presenting with right ureter hydronephrosis: A case report. Gynecol Oncol Rep 2020; 34:100639. [PMID: 32995453 PMCID: PMC7508993 DOI: 10.1016/j.gore.2020.100639] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 09/02/2020] [Accepted: 09/06/2020] [Indexed: 11/18/2022] Open
Abstract
Primary lymphoma of the uterine cervix is a very infrequent disease, usually affecting perimenopausal women. Symptoms are very similar to other gynecological malignancies, but treatment and prognosis completely differ, as most of these patients have a better survival. This condition has to be suspected in women with recent normal Pap smear test, rapidly growing tumor and initially non-contributory biopsies. We report a case of primary diffuse large-B-cell lymphoma of the uterine cervix mimicking a locally advanced cervical cancer with right ureter hydronephrosis at diagnosis. She was medically managed with a combination of rituximab and chemotherapy with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone, associated to methotrexate for central nervous system prophylaxis. We will discuss about the role of combined treatments with surgery and radiotherapy, and the fertility sparing management in young women.
Collapse
Affiliation(s)
- Mathilde Del
- Department of Surgical Oncology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
| | - Martina Aida Angeles
- Department of Surgical Oncology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
| | - Charlotte Syrykh
- Department of Pathology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
| | - Carlos Martínez-Gómez
- Department of Surgical Oncology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
- INSERM CRCT Team 1, Tumor Immunology and Immunotherapy, Toulouse, France
| | - Alejandra Martínez
- Department of Surgical Oncology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
- INSERM CRCT Team 1, Tumor Immunology and Immunotherapy, Toulouse, France
| | - Gwénaël Ferron
- Department of Surgical Oncology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
- INSERM CRCT Team 19, ONCOSARC – Oncogenesis of sarcomas, Toulouse, France
| | - Erwan Gabiache
- Department of Nuclear Medicine, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
| | - Lucie Oberic
- Department of Hematology, Institut Claudius Regaud – Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole, Toulouse, France
| |
Collapse
|
24
|
Jacquier A, Syrykh C, Bedgedjian I, Monnien F, Laurent C, Valmary-Degano S, Brousset P. Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma. J Clin Pathol 2020; 74:jclinpath-2020-206747. [PMID: 32839159 PMCID: PMC8142454 DOI: 10.1136/jclinpath-2020-206747] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 07/03/2020] [Accepted: 07/07/2020] [Indexed: 01/16/2023]
Abstract
AIMS Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS In this study, we sought to determine precise PMBL phenotype, compared with diffuse large B-cell lymphoma not otherwise specified, by combining immunohistochemistry with anti-MAL antibody and RNA in situ hybridisation (RNAscope) with specific MAL probes. RESULTS The overall MAL positivity level reached 93% (14/15) of cases of PMBL. Among the 15 cases enrolled in the study, 11 were undoubtedly positive for MAL immunostaining whereas 13 were positive by RNA in situ hybridisation. Interestingly, one case that was negative by in situ hybridisation turned out to be positive by immunohistochemistry. CONCLUSIONS Taken together, our results demonstrate that in situ detection of both MAL transcripts and protein are complementary and increase the sensitivity and specificity of PMBL diagnosis.
Collapse
Affiliation(s)
- Anthony Jacquier
- Department of Pathology, University Hospital of Besancon, Besancon, France
| | - Charlotte Syrykh
- Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France
| | | | - Franck Monnien
- Department of Pathology, University Hospital of Besancon, Besancon, France
| | - Camille Laurent
- Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France
| | | | - Pierre Brousset
- Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France
| |
Collapse
|
25
|
Aroua N, Boet E, Ghisi M, Nicolau-Travers ML, Saland E, Gwilliam R, de Toni F, Hosseini M, Mouchel PL, Farge T, Bosc C, Stuani L, Sabatier M, Mazed F, Larrue C, Jarrou L, Gandarillas S, Bardotti M, Picard M, Syrykh C, Laurent C, Gotanègre M, Bonnefoy N, Bellvert F, Portais JC, Nicot N, Azuaje F, Kaoma T, Joffre C, Tamburini J, Récher C, Vergez F, Sarry JE. Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. Cancer Discov 2020; 10:1544-1565. [PMID: 32641297 DOI: 10.1158/2159-8290.cd-19-1008] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 05/09/2020] [Accepted: 07/02/2020] [Indexed: 11/16/2022]
Abstract
Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell-surface expression and activity is increased in patients with AML upon chemotherapy compared with diagnosis, and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes cytarabine resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated adaptive mitochondrial stress response. Finally, genetic and pharmacologic inhibition of CD39 ecto-ATPase activity blocks the mitochondrial reprogramming triggered by cytarabine treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new residual disease marker and a promising therapeutic target to improve chemotherapy response in AML. SIGNIFICANCE: Extracellular ATP and CD39-P2RY13-cAMP-OxPHOS axis are key regulators of cytarabine resistance, offering a new promising therapeutic strategy in AML.This article is highlighted in the In This Issue feature, p. 1426.
Collapse
Affiliation(s)
- Nesrine Aroua
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Emeline Boet
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Margherita Ghisi
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Marie-Laure Nicolau-Travers
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Estelle Saland
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Ryan Gwilliam
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Fabienne de Toni
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Mohsen Hosseini
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Pierre-Luc Mouchel
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Thomas Farge
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Claudie Bosc
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Lucille Stuani
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Marie Sabatier
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Fetta Mazed
- Institut Cochin, Département Développement, Reproduction, Cancer, UMR8104-CNRS, U1016-INSERM, Paris.,Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Clément Larrue
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Latifa Jarrou
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Sarah Gandarillas
- Centre Régional d'Exploration Fonctionnelle et Ressources Expérimentales, Service d'Expérimentation Animale, UMS006, Inserm, Toulouse, France
| | - Massimiliano Bardotti
- Centre Régional d'Exploration Fonctionnelle et Ressources Expérimentales, Service d'Expérimentation Animale, UMS006, Inserm, Toulouse, France
| | - Muriel Picard
- University of Toulouse, Toulouse, France.,Intensive Care Unit, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Charlotte Syrykh
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Anatomopathologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Anatomopathologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Mathilde Gotanègre
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Nathalie Bonnefoy
- Institut de Recherche en Cancérologie de Montpellier, U1194, Inserm, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France
| | | | | | - Nathalie Nicot
- LuxGene, Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Francisco Azuaje
- Computational Biomedicine Research Group, Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Tony Kaoma
- Computational Biomedicine Research Group, Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Carine Joffre
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France
| | - Jérome Tamburini
- Institut Cochin, Département Développement, Reproduction, Cancer, UMR8104-CNRS, U1016-INSERM, Paris.,Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Christian Récher
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - François Vergez
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France.,University of Toulouse, Toulouse, France.,Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - Jean-Emmanuel Sarry
- Centre de Recherches en Cancérologie de Toulouse, UMR1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 CNRS, Equipe Labellisée LIGUE 2018, Toulouse, France. .,University of Toulouse, Toulouse, France
| |
Collapse
|
26
|
Syrykh C, Abreu A, Amara N, Siegfried A, Maisongrosse V, Frenois FX, Martin L, Rossi C, Laurent C, Brousset P. Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning. NPJ Digit Med 2020; 3:63. [PMID: 32377574 PMCID: PMC7195401 DOI: 10.1038/s41746-020-0272-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 03/23/2020] [Indexed: 01/03/2023] Open
Abstract
Histopathological diagnosis of lymphomas represents a challenge requiring either expertise or centralised review, and greatly depends on the technical process of tissue sections. Hence, we developed an innovative deep-learning framework, empowered with a certainty estimation level, designed for haematoxylin and eosin-stained slides analysis, with special focus on follicular lymphoma (FL) diagnosis. Whole-slide images of lymph nodes affected by FL or follicular hyperplasia were used for training, validating, and finally testing Bayesian neural networks (BNN). These BNN provide a diagnostic prediction coupled with an effective certainty estimation, and generate accurate diagnosis with an area under the curve reaching 0.99. Through its uncertainty estimation, our network is also able to detect unfamiliar data such as other small B cell lymphomas or technically heterogeneous cases from external centres. We demonstrate that machine-learning techniques are sensitive to the pre-processing of histopathology slides and require appropriate training to build universal tools to aid diagnosis.
Collapse
Affiliation(s)
- Charlotte Syrykh
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
| | - Arnaud Abreu
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
- Roche Institute, Boulogne-Billancourt, France
- ICube, University of Strasbourg, CNRS, Strasbourg, France
| | - Nadia Amara
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
| | - Aurore Siegfried
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
| | - Véronique Maisongrosse
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
| | - François X. Frenois
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
| | - Laurent Martin
- Department of Pathology, Dijon University Hospital, Dijon, France
- INSERM UMR 1231, Dijon, France
| | - Cédric Rossi
- INSERM UMR 1231, Dijon, France
- Department of Haematology, Dijon University Hospital, Dijon, France
| | - Camille Laurent
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
- INSERM UMR 1037 Cancer Research Centre of Toulouse (CRCT), University of Toulouse III Paul-Sabatier, National Centre for Scientific Research (CNRS ERL 5294), Toulouse, France
- Laboratoire d’Excellence ‘TOUCAN’, Institut Carnot Lymphome CALYM, Toulouse, France
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR (University Hospital Oncology Programme), Toulouse, France
| | - Pierre Brousset
- Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France
- INSERM UMR 1037 Cancer Research Centre of Toulouse (CRCT), University of Toulouse III Paul-Sabatier, National Centre for Scientific Research (CNRS ERL 5294), Toulouse, France
- Laboratoire d’Excellence ‘TOUCAN’, Institut Carnot Lymphome CALYM, Toulouse, France
| |
Collapse
|
27
|
Péricart S, Syrykh C, Amara N, Franchet C, Malavaud B, Gaulard P, Girard JP, Ysebaert L, Laurent C, Brousset P. Exclusive B-cell phenotype of primary prostatic lymphomas: a potential role of chronic prostatitis. Histopathology 2020; 76:767-773. [PMID: 31825109 DOI: 10.1111/his.14045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 12/09/2019] [Indexed: 11/30/2022]
Abstract
AIMS Primary prostatic lymphomas (PPL) is exceedingly rare. The aim of this study was to investigate the largest series of PPL obtained from a nationwide expert pathologist network, and thus try to understand the pathophysiology of these tumours. METHODS AND RESULTS Up to 66 000 lymphoma cases have been collected and submitted for central expert review by the French Lymphopath network. We confirm the low frequency of PPL (n = 77; 0.12%), all cases being of B-cell origin. Diffuse large B-cell lymphoma and small lymphocytic lymphoma were the most frequent subtypes, comprising 31% and 26% of cases respectively, followed by mucosa-associated lymphoid tissue (MALT)/lymphoplasmacytic lymphoma (19%), follicular lymphoma (12%), mantle cell lymphoma (6%), Burkitt lymphoma (4%), and unclassified lymphoma (1%). Clinical data obtained in 25 cases suggests that PPLs are rather indolent tumours. Our hypothesis for B-cell recruitment in the prostatic tissue was derived from the observation in chronic inflammation (prostatitis) of frequent heterotopic proliferation of high endothelial venules (HEVs). The latter are dedicated to lymphocyte entry into secondary lymphoid organs, here putatively driving circulating clonal B-lymphocytes from the blood into the inflamed prostate. This may account for the relatively high incidence of small lymphocytic lymphoma consistently reported in series of primary or secondary prostatic lymphoma. As in other organs or glands, chronic inflammation may promote antigen-dependent intraprostatic MALT lymphoma and diffuse large B-cell lymphoma development. CONCLUSIONS PPLs are exclusively of B-cell origin, and chronic inflammation resulting from the proliferation of high endothelial venules could play some role in their development.
Collapse
Affiliation(s)
- Sarah Péricart
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| | - Charlotte Syrykh
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| | - Nadia Amara
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| | - Camille Franchet
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| | | | - Philippe Gaulard
- Department of Pathology, Hôpital Henri Mondor, Créteil, France.,INSERM U955, Université Paris Est, Créteil, France
| | - Jean-Philippe Girard
- Labex TOUCAN, Toulouse, France.,Institut de Pharmacologie et de biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Loic Ysebaert
- Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Department of Haematology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Camille Laurent
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| | - Pierre Brousset
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Cancer Research Centre of Toulouse, INSERM UMR1037, Toulouse, France.,Labex TOUCAN, Toulouse, France
| |
Collapse
|
28
|
Brousset P, Syrykh C, Abreu A, Amara N, Laurent C. DIAGNOSIS AND CLASSIFICATION ASSISTANCE FROM LYMPHOMA MICROSCOPIC IMAGES USING DEEP LEARNING. Hematol Oncol 2019. [DOI: 10.1002/hon.97_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Brousset
- Pathology; IUCT-Toulouse Oncopole; Toulouse France
| | - C. Syrykh
- Pathology; IUCT-Toulouse Oncopole; Toulouse France
| | - A. Abreu
- Pathology; IUCT-Toulouse Oncopole; Toulouse France
| | - N. Amara
- Pathology; IUCT-Toulouse Oncopole; Toulouse France
| | - C. Laurent
- Pathology; IUCT-Toulouse Oncopole; Toulouse France
| |
Collapse
|
29
|
Aselmaa A, van Herk M, Laprie A, Nestle U, Götz I, Wiedenmann N, Schimek-Jasch T, Picaud F, Syrykh C, Cagetti LV, Jolnerovski M, Song Y, Goossens RH. Using a contextualized sensemaking model for interaction design: A case study of tumor contouring. J Biomed Inform 2017; 65:145-158. [DOI: 10.1016/j.jbi.2016.12.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Revised: 11/02/2016] [Accepted: 12/04/2016] [Indexed: 12/28/2022]
|